Biotechnology company focused on developing novel oncology therapies.
Apogee Therapeutics, Inc., operating through its subsidiary, is a pioneering biotechnology firm focused on advancing biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunological conditions. Established in 2022 and based in Waltham, Massachusetts, the company is committed to developing innovative therapeutic solutions.
At the forefront of its pipeline is APG777, an extended half-life monoclonal antibody (mAb) administered subcutaneously for the treatment of AD. Additionally, Apogee Therapeutics is advancing APG808, another subcutaneous extended half-life mAb specifically designed for patients with COPD, addressing critical needs in respiratory care.
The company's early-stage programs include APG990, an extended half-life mAb aimed at further enhancing treatment options for AD, underscoring its dedication to expanding therapeutic possibilities. Furthermore, Apogee Therapeutics is developing APG222, which also utilizes extended half-life subcutaneous antibodies targeting AD, demonstrating its commitment to advancing treatment efficacy and patient outcomes in dermatological care.
With a strong foundation in biotechnology and a strategic focus on addressing unmet medical needs in chronic inflammatory conditions, Apogee Therapeutics continues to drive innovation in the field. By leveraging cutting-edge research and development, the company aims to significantly impact the lives of patients worldwide through its novel biologic therapies.